672 related articles for article (PubMed ID: 23286431)
1. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Riva N; Lip GY
Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy as first-line treatment for hypertension.
Crawford MH
Am J Cardiovasc Drugs; 2009; 9(1):1-6. PubMed ID: 19178127
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
4. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
5. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
6. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
7. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
8. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
Roberts ME; Epstein BJ
J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
[TBL] [Abstract][Full Text] [Related]
9. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
Bramlage P
Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
[TBL] [Abstract][Full Text] [Related]
11. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
12. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
13. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
Reboldi G; Gentile G; Angeli F; Verdecchia P
Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y;
Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
Weir MR; Bakris GL
J Clin Hypertens (Greenwich); 2008 Feb; 10(2):146-52. PubMed ID: 18256579
[TBL] [Abstract][Full Text] [Related]
16. Cochrane in context: pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
[TBL] [Abstract][Full Text] [Related]
17. Management of hypertension with fixed-dose triple-combination treatments.
Epstein BJ; Shah NK; Borja-Hart NL
Ther Adv Cardiovasc Dis; 2013 Oct; 7(5):246-59. PubMed ID: 23945906
[TBL] [Abstract][Full Text] [Related]
18. Hypertension management: rationale for triple therapy based on mechanisms of action.
Neutel JM; Smith DH
Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
[TBL] [Abstract][Full Text] [Related]
19. Update on the management of hypertension: recent clinical trials and the JNC 7.
Moser M
J Clin Hypertens (Greenwich); 2004 Oct; 6(10 Suppl 2):4-13. PubMed ID: 15470293
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence?
Taddei S
Am J Cardiovasc Drugs; 2015 Jun; 15(3):185-94. PubMed ID: 25850749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
